Enovix shares fell 28.5% after earnings. The transcript points to a key concern: revenue was only $11 million, which management itself described as a “little league” quarter, while the breakeven vision remains beyond 2027 and depends on substantial future revenue growth.
Enovix shares dropped 8.3% as investors reacted negatively to cautious outlook signals and margin pressures despite modest revenue growth and initial commercial traction, suggesting the company’s longer path to smartphone commercialization and uncertain near-term profitability weighed on sentiment.
Enovix shares fell 13.6% as investors reacted negatively to cautious commentary on commercialization timelines and margin pressures despite progress in customer engagements and manufacturing. The market clearly signaled disappointment with the pace of scale and the lack of clear near-term revenue acceleration.
Enovix Corporation delivered robust growth in Q3 2025, with revenue increasing 85% year-over-year to $8 million and achieving a significant gross profit margin while positioning itself strongly for future advancements in battery technology.